Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Interruption of Radiation Therapy Risks Cancer Recurrence

February 10, 2016 By Montefiore Medical Center

Cancer patients who miss two or more radiation therapy sessions have a worse outcome than fully compliant patients, investigators at Montefiore Einstein Center for Cancer Care (MECCC) and Albert Einstein College of Medicine’s NCI-designated Albert Einstein Cancer Center have found. The study, published in the International Journal of Radiation Oncology Biology Physics, suggests that this noncompliance to scheduled treatments may represent a new behavioral biomarker for identifying high-risk patients who require additional interventions to achieve optimal care outcomes.

The study evaluated 1,227 patients scheduled for courses of external beam radiation therapy for cancers of the head and neck, breast, lung, cervix uterus or rectum from 2007 to 2012. Two hundred twenty six of these patients (22 percent) were noncompliant (i.e., they missed two or more scheduled radiation therapy appointments). All patients eventually completed the radiation therapy course planned for them.

The radiation therapy course for noncompliant patients was prolonged for an average of one week compared with compliant patients. Nevertheless, 16 percent of noncompliant patients later experienced a recurrence of their cancers versus only a 7 percent recurrence rate for compliant patients.

“This study shows that the health of our patients can improve only when a course of treatment is completed in the prescribed period of time,” said Madhur Garg, M.D., clinical director, Department of Radiation Oncology, MECCC and professor of clinical radiation oncology at Einstein. “These findings should serve as a wakeup call to physicians, patients and their caregivers about the critical need to adhere to a recommended treatment schedule.”

Prolonging radiation therapy for head and neck cancer or cervical cancer impacted tumor control and overall survival at the greatest rate, at one percent per day, however this negative impact was seen in all cancers studied. This is attributed to tumor repopulation, which can accelerate after treatment initiation.

“We previously conducted a study that demonstrated a statistically significant relationship between lower socioeconomic status and non-compliance,” said Nitin Ohri, M.D., attending physician, MECCC and assistant professor of radiation oncology at Einstein. “A Multivariable Cox proportional hazard model was informed by this prior study and helped us adjust for demographic variables like age, race, ethnicity and socioeconomic status.”

As an outcome result of this study, management of mood disorders, patient navigator programs and increasing assistance with transportation are being evaluated at Montefiore as interventions that might improve patient care outcomes and close disparities among vulnerable populations.

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech